ABSTRACT Aim: Alzheimer's disease is characterized by pathological protein aggregates and microglia-driven chronic neuroinflammation. Cathepsin B has been proposed as the potential target for inhibiting adverse activation of microglia and slowing down this neurodegenerative disease. Currently available inhibitors of cathepsin B enzymatic activity are non-selective; therefore, the design and synthesis of novel specific inhibitors could facilitate the development of a new class of anti-Alzheimer medications targeting the neuroinflammatory component of this disease.
INTRODUCTION
Alzheimer's disease is the most common cause of dementia. It is characterized by abnormal brain protein deposits including amyloid ß (Aß)-containing plaques and neurofibrillary tangles. In addition, chronic neuroinflammation, driven by adverse activation of non-neuronal microglial cells, is believed to contribute to the pathogenesis of this neurodegenerative disease. Microglial immune functions can be regulated by various cathepsin enzymes, many of which are the components of lysosomes [1, 2] . Cathepsins belong to the papain superfamily and are synthesized as inactive pro-enzymes [3] . Cathepsin B, a cysteine protease, is expressed and can be secreted by activated microglia [4] [5] [6] [7] . Cathepsin B has been proposed as a potential therapeutic target to reduce neuroinflammation in Alzheimer's disease [8] based on observations showing this protein upregulated in brain tissues, serum and cerebrospinal fluid of Alzheimer's patients [9] [10] [11] [12] [13] . Such high levels of cathepsin B also correlate with decreased cognition, which could be caused by adverse microglia activation [11, 14] .
A series of pre-clinical studies support using cathepsin B inhibitors to slow the progression of Alzheimer's disease. Reduced Aß plaque load and improved memory were reported in a transgenic Alzheimer mice model after deleting the cathepsin B gene [15] . In vitro studies showed that cathepsin B inhibitors downregulated pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1ß, and IL-18 [16] [17] [18] . Cathepsin B has been linked to specific microglial functions including their secretion of cytokines, neurotoxicity, and Aß degradation [5, 17, 19] . Currently available cathepsin B inhibitors are not specific since they inhibit enzymatic activity of other cysteine proteases including calpains, as well as cathepsins S and L [3, [20] [21] [22] [23] . Therefore, novel highly selective cathepsin B inhibitors should be developed and tested for their ability to ameliorate neuroinflammation in neurodegenerative diseases.
Cathepsin B enzymatic activity is inhibited by alpha-macroglobulin from the cystatin family of inhibitors of papain-like cysteine peptidases, and by representatives of the equistatin family [24] . There are three additional groups of naturally occurring cathepsin B inhibitors: the aziridinyl peptides, peptide epoxysuccinyls, and peptide aldehydes [25, 26] . Known synthetic cathepsin B inhibitors can be divided into groups of compounds, which contain either flavonoids, cyclic sulfates, or nitriles [27, 28] . Cathepsins B and K are inhibited with reasonable potency by gold(I)-based compounds such as auranofin (Ridaura), which is clinically used as an anti-rheumatic agent, and its analogs [29] . Structure-activity relationship (SAR) studies revealed that replacement of ethyl substituent with a voluminous aryl substituent in auranofin, which is a clinically approved triethylphosphine (PEt 3 ) gold-containing drug, significantly increased its anti-inflammatory activity [30] . A triphenylphosphine gold compound was shown to be a more effective cathepsin B inhibitor (IC 50 = 337 nmol/L) than its parent compound auranofin (IC 50 > 250 µmol/L) [30] . Further studies confirmed that compounds with more than one aryl group (e.g., triarylphosphines) were much stronger cathepsin B inhibitors than triethylphosphine Au(I)-containing derivatives [31] .
In this study, we describe an in silico model developed for identification of pharmacophores capable of increasing the biological activity of Au(I)-based drug-like compounds. Previously, it was shown that changes in steric and electronic properties of phosphine derivatives led to increased affinity of these compounds toward cathepsin B [31] . The aim of the present study was to develop and test novel structural modifications of cathepsin B inhibitors, which could be used for synthesis of new, potentially more effective anti-neuroinflammatory drugs. To achieve this goal, we first developed an in silico docking model of the cathepsin B enzymatic pocket. Subsequently, a series of novel cathepsin B inhibitors were designed and synthesized, based on their calculated binding affinity to the enzymatic pocket and docking scores. An in vitro testing of selected compounds as possible cathepsin B inhibitors was also performed.
METHODS

In silico modeling
All manipulations with protein-ligand structures and generation of structural models of cathepsin-ligand complexes were performed with Sybyl-X software (Tripos Inc., St. Louis, MO, USA). The three-dimensional structure of the triethylphosphine was generated by the CONCORD version 3.0 software (CONCORD, St Louis, MO, USA). Ligand topologies for molecular dynamics (MD) studies were calculated using the antechamber module of AmberTools version 12 [32] . The protein structures of cathepsins B and K (Protein Data Bank Identifiers (PDB IDs): 1HUC and 2ATO) were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB, www.rcsb.org) [33] . Structures of the complexes formed by cathepsin B interacting with triethylphosphine, as well as cathepsin K with myochrysine (Au-thiomalate), were modeled in the experiment. The subsequent steps of the relaxation strategy for the structural optimization of active site geometry were carried out with Gromacs (version 4.5) software with implementation of Amber99 force field [34] .
Due to the absence of defined atom-type and coordination bonding parameters for Au in both MD and docking software, we utilized fragment-based docking methods for the model development. Replacement of the Au atom with a CF 3 group, which has four heavy atoms, allowed us to preserve both geometry and distances between the ligand and C-alpha of the catalytic residue Cys29 (C29) in the cathepsin B molecule [ Figure 1 ]. As a result of this manipulation, a "joint-like" metal-based binding of Au was replaced with the "anchor-like" binding mode of CF 3 . Additional mutation of the catalytic cysteine (C29) to alanine (C29A) provided more flexibility for the CF 3 -containing ligands and avoided artificial interaction between the sulfur atom of C29 and the CF 3 group.
In order to remove any unfavorable steric clashes between the proteases and the inhibitor molecules, 1000 steps of steepest descent and 5000 steps of conjugate-gradient energy minimization were employed. The complex between cathepsin B and triethylphosphine was solvated with a 12 Å radius water box centered at the C29A. A center of mass (COM) pulling mode was applied during all steps of MD calculations to improve the geometry of the P-CF 3 -C-alpha (CA, of alanine) bridge. The optimized and equilibrated system was used as the starting configuration for MD simulations spanning 500 ps. Such fast molecular dynamics was enough to stabilize the group of constrained P-CF 3 -CA atoms. Average root-mean-square deviation (RMSD) values for the whole structure, including the active site and ligand atoms, were calculated from each of the five picoseconds frames of the simulation. RMSD values, together with the structure alignment, confirmed that conformation of the ligand and the active site of protein had not changed dramatically and were considered stable enough to continue modeling.
For the docking procedure, a specific binding site representation (namely Protomol) was generated based on the relaxed protein-ligand complex. Protomol is an interaction map, implemented in the Surflex-Dock module, which is based on the probing method used [35] . Protomol model is very sensitive to input parameters; therefore, to avoid mistakes in predictions, it was parameterized based on scores obtained through validation docking procedures. To keep the amino acid environment flexible during each docking run, the most reliable positions of the reference PEt 3 were retained with the number of starting conformations per ligand higher than ten. The new compounds were designed based on the shape of the binding pocket and its hydrophobic/hydrophilic areas.
A set of reference compounds was compiled from publicly available structures and contained the triethylphosphine molecule and its modifications. Structures of these reference compounds and their corresponding IC 50 values as cathepsin B inhibitors have been previously published [36] . Predictions from the docking studies were made based on correlations between docking scores and known enzymatic activity of the reference compounds. Surflex-Dock scores (total score expressed in: -log 10 (K d ) units) represented the binding affinities. Four different calculated parameters were used as the most important indicators in docking analysis: "total score", "crash value" (the degree of inappropriate penetration by the ligand into the protein; values close to zero are favorable), "internal ligand strain" and "complex absolute energy". In addition, the root-mean-square (RMS) distance between the docked ligand and the reported fragment RMSD (FragRMSD) was calculated to provide the correct orientation of the ligand in the binding site.
In vitro testing
Cathepsin B enzymatic activity was measured as described by Hulkower et al. [37] (2000) with modifications. A fluorometric assay was used in which cathepsin B (from bovine spleen) cleaved its substrate, Z-Arg-Arg-AMC (both from Sigma Aldrich, Oakville, ON, Canada), causing the cleaved product to fluoresce. The reaction was performed in Hanks' balanced salt solution containing 0.6 mmol/L CaCl 2 , 0.6 mmol/L MgCl 2 , 2 mmol/L L-cysteine, and 25 mmol/L PIPES, pH 7.0. The assay was performed in a 96-well plate, and the POLARstar Omega plate reader (BMG Labtech, Durham, NC, USA) with an excitation wavelength of 355 nm and an emission wavelength of 460 nm was used to measure the velocity of the reaction (relative fluorescence units per min) at 37 °C. Au-containing substances were dissolved in dimethyl sulfoxide (DMSO) and added to the reaction mixture at 10 nM to 500 μmol/L concentration range. The final concentration of the solvent in the reaction mixture did not exceed 0.5%. The solutions containing cathepsin B (200 μg/mL) and the inhibitors were allowed to incubate for 30 min at 37 °C. Subsequently Z-Arg-Arg-AMC (from a 600 μmol/L stock solution) was added to the wells to reach the final concentration of 30 μmol/L in a total well volume of 180 μL. The 96-well plate was then positioned into the plate reader and fluorescence measurements from each well were recorded. The plate reader was set to acquire 64 measurements over a 52-min time frame. The maximum slope values of the samples containing inhibitors were calculated as percentages of maximum slope values of the control samples containing DMSO vehicle solution only, and IC 50 values for each inhibitor determined. 
RESULTS
Proper selections of binding sites, together with a good understanding of the mechanism of enzymatic activity of cathepsins, are the key factors for designing effective new inhibitors; however, currently available inhibitors of cathepsin B are only 2-to 8-fold more selective towards this enzyme compared to two other cathepsins S or L [3, 22] . It was previously shown that cathepsin B is reversibly and competitively inhibited by linear Au(I)-containing complexes [29] . A hit-to-lead optimization of the organic ligands used to create new auranofin analogs, particularly the phosphine ligands, could significantly increase the potency of these compounds as cathepsin B inhibitors. Phosphine ligand interaction with cathepsin B was modeled based on the myochrysine (Au-thiomalate) binding to cathepsin K [31] . The crystal structure of the 339 amino acid-long human liver cathepsin B has been published at a 1.9 Å resolution (PDB ID: 1GYM) [38] . Access to the active site of cathepsin B is provided by an 18 amino acid long insertion (Pro107 Asp124), termed the occluding loop, which possesses two His residues for binding of the carboxyl group of the substrate. Three-dimensional alignment of the crystal structures of cathepsins B, S, K and L demonstrated a considerable degree of homology, especially in the region of substrate binding. Our molecular modeling identified that the potential binding site on the surface of cathepsins is represented by a long hydrophobic pocket, which is necessary for the peptide binding and excision. Figure 2 shows that the structures of cathepsins K and B are very similar, including their cleavage sites containing several "hot-spot" amino acids conserved among all types of cathepsins, along with Cys29, which forms a coordination bond with PEt 3 .
Despite the great variety of protein modeling tools and techniques available, there is no simple approach to study interactions between Au-containing compounds and proteins without the time-consuming quan- tum mechanics (QM) calculations. The absence of Au or any cognate element and its bond parameters in most force field and docking protocols compelled us to implement several alternative techniques, known as steered molecular dynamics and fragment-based docking approach, as suitable models for docking and subsequent lead optimization. A structure preparation tool from SybylX suite was used to model the complex between cathepsin B and Au-containing ligand. A crystal structure of cathepsin B (PDB ID: 1HUC) was superimposed on the cathepsin K structure (PDB ID:2ATO) and coordinates of co-crystalized myochrysine (Au-thiomalate) and cathepsin B were saved for subsequent analyses. The highly conserved cysteine, histidine and asparagine residues from the active site of cathepsins B and K were used for structure superposition.
The measured essentially important linear angle between the atoms in the S-Au-S triad (sulfur of C25, Au(I) and sulfur of thiomalate) of the complex between cathepsin K and Au-thiomalate was 173.1 o . Subsequently, the gold atom in Au-thiomalate was replaced with a CF 3 group. CF 3 is a directional and rigid group, which has a binding mode similar to the gold atom. The CF 3 possesses four tetrahedral heavy atoms, which are necessary for accurate geometric constraints as well as the bond-like rotation during molecular dynamics and docking. In addition, the Cys25 residue in the enzymatic pocket of cathepsins B and K was replaced with alanine to eliminate a steric clash and electrostatic interactions with the CF 3 group of thiomalate. In order to validate the docking procedure, a model of cathepsin K was developed based on its complex with CF 3 -containing Au-thiomalate. Subsequently, CF 3 -containing Au-thiomalate in this complex was replaced with CF 3 -substituted triethylphosphine.
The fast molecular dynamics simulation, spanning 500 ps, generated parameters of trajectories, which were analyzed and clustered by RMSD to identify the most stable conformation of the complexes. The docking model of cathepsin B was developed based on this structure. Figure 3 shows the resulting modified compound CF 3 -PEt 3 positioned in the mutated (C29A) enzymatic pocket of cathepsin B, with preserved original geometry (position and orientation) of the PEt 3 group. This structure maintained all the distances and colinear characteristics of the complex between CF 3 -substituted triethylphosphine and cathepsin B. The volume of the cathepsin B active site was defined with a Protomol generation tool.
Next, to provide ligand dislocation similar to that in the CF 3 -substituted complex between triethylphosphine and cathepsin B, we applied both the distance and position constraints. The P atom -CF 3 fragment was assigned as a constraint in Surflex-Dock, to match the correct position and orientation of the ligands in the enzymatic pocket. After several test dockings we chose an appropriate value for "cpen" function (penalty for deviating from fragment), which determines how closely compounds could be positioned to the source coordinates of the template P-CF 3 group of six different CF 3 -substituted auranofin derivatives. Reference compounds . Through the design of novel compounds, we aimed to improve their cathepsin B binding affinities. The three-dimensional structure of the new compounds was generated by the CONCORD (see Methods section). We chose a triphenylphosphine (PPh3) as the initial structure for design, since previous studies [29] confirmed its significant in vitro activity as an inhibitor of cathepsin B enzymatic activity. The validation step of the fragment-based docking defined optimal software settings, which provided the best correlation between the enzymatic activity inhibition data and the docking score [ Table 1 ]. Table 1 lists a set of compounds with known IC 50 values in cathepsin B enzymatic assays. This table also includes the previously reported compound triethylphosphine (P(CH 2 CH 3 ) 3 ) and its analogs with substituted methyl groups on phenyl rings [31] . Table 1 likewise includes examples of newly synthesized compounds (Cmpd 1-6). These novel derivatives were created by replacing the triethylphosphine ligand of the auranofin molecule with other phosphines carrying various aromatic and heteroaromatic substituents. Table 1 is divided into seven columns and the most practical parameter for the docking analysis outcome is the summarized score (total score), which is an empirical affinity value developed to predict the potency of the inhibitors. This value is calculated based on the other parameters shown in this table. The upper part of the table illustrates correlations between scores obtained from in silico modeling and in vitro testing described in published studies and patents [31, 36, 40] . The lower part of the table shows predicted affinities and the measured cathepsin B inhibitor activities for the newly synthesized compounds. The validation step was complete after confirmation of a relationship between the calculated and biochemically determined values for known inhibitors. These two parameters are listed in Table 1 and compounds are sorted in order of ascending IC 50 values in cathepsin B enzymatic activity assay, which correlate inversely (negative correlation coefficient of -0.71) with the calculated total score values.
In addition, we repeated all docking procedures with cathepsin K, exactly as they were described for cathepsin B above, by applying match constraining to CF 3 . In this way, we compared the results of our MD modeling for both proteins, which showed different docking scores for the interactions between the substituted triethylphosphine derivatives and cathepsin K [ Table 2 ]. These data indicate a certain degree of selectivity towards a specific cathepsin isoform for these compounds.
Three-dimensional alignments of docked reference inhibitors in the active site of cathepsin B are presented in Figure 3 . RMSD values for the compounds used to estimate the three-dimensional matching of the reference arylphosphine derivatives to substituted triethylphosphine are listed in Table 1 . After the initial lead compound optimization and docking, a limited set of seven substituted phosphines were synthesized from a total of 15 designed structures and used for in vitro studies. The best way of comparing the overall calculated binding affinities of ligands is a comparison of their total score values. However, all other scoring functions can be useful in specific cases. For example, as can be seen from Table 1 , the best experimental and docking results were obtained for P(C 6 H 4 NH 3 + )(C 6 H 5 ) 2 compound. It is evident that high total scores and low internal strain scores are preferable for the newly developed compounds. Therefore, these parameters were used for the further design of the improved novel drug-like compounds. Further optimization and improvement of each drug-like compound were based on their spatial location in the enzymatic pocket of cathepsin B and compliance to the physical features of the active site, including anchoring with the CF 3 group and localization of phosphine groups in the hydrophobic/hydrophilic regions of the enzymatic pocket.
DISCUSSION
Our data show that the described docking model is a practical tool for identification and optimization of novel compounds, which have been designed based on their phosphine core structure. We also focused our attention on the shape features of the cathepsin B binding site and achieved a good trend in selectivity of the inhibitors towards this enzyme, by avoiding their binding to cathepsin K. The inverse correlation (-0.71) between docking scores of compounds and their IC 50 values as well as significant selectivity towards cathepsin B and not cathepsin K [ Tables 1 and 2 ] supported subsequent docking analysis and selection of compounds for in vitro testing. Thus, by using the molecular modeling described in this study we were able to design and create structurally novel derivatives of the clinically available anti-rheumatic drug auranofin, which inhibited the enzymatic activity of cathepsin B more effectively than their parent drug. It has been established that the clinical anti-inflammatory activity of auranofin depends on its ability to affect multiple cellular and molecular targets [41] . Even though clinical effectiveness of auranofin in neurodegenerative disorders has not been studied, its anti-inflammatory activity may be beneficial for slowing down neuroinflammation accompanying such pathologies as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis [42] . Optimizing the activity and selectivity of auranofin molecule as an inhibitor of cathepsin B through structural modifications may lead to additional benefits of such novel compounds in Alzheimer's disease in particular [43] . Further in vivo studies will be required to determine the pharmacokinetics and pharmacodynamics of these novel derivatives of auranofin, as well as their clinical suitability as anti-neuroinflammatory drugs and cathepsin B inhibitors.
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